Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Adaptimmune Therapeutics Plc - ADR?
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Adaptimmune Therapeutics Plc - ADR market cap is $7.95M.
What is the 52-week high for Adaptimmune Therapeutics Plc - ADR?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Adaptimmune Therapeutics Plc - ADR 52 week high is $0.2384 as of October 10, 2026.
What is the 52-week low for Adaptimmune Therapeutics Plc - ADR?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Adaptimmune Therapeutics Plc - ADR 52 week low is $0.0001 as of October 10, 2026.
What is Adaptimmune Therapeutics Plc - ADR stock price today?
Adaptimmune Therapeutics Plc - ADR stock price today is $0.03.
What was Adaptimmune Therapeutics Plc - ADR stock price yesterday?
Adaptimmune Therapeutics Plc - ADR stock price yesterday was $0.028.
What is the 50-day moving average of Adaptimmune Therapeutics Plc - ADR?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Adaptimmune Therapeutics Plc - ADR 50-day moving average is $0.0275.